Severe atovaquone-resistant Plasmodium falciparum malaria in a Canadian traveller returned from the Indian subcontinent

Open Medicine

Volumn 3, Issue 1, 2009, Pages 10-16

  Perry, Thomas L ^a   Pandey, Prativa ^b   Grant, Jennifer M ^c   Kain, Kevin C ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CIWEC Travel Medicine Centre Nepal   (Nepal)

^c Division of Microbiology and Infection Control   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58749105670     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Mühlberger N, Jelinek T, Behrens RH, Gjørup I, Coulaud JP, Clerinx J, et al. Surveillance importierter Infektionen in Deutschland Surveillance Networks. Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis. 2003;36(8):990-995.
2. Kain KC, Harrington MA, Tennyson S, Keystone JS. Imported malaria: prospective analysis of problems in diagnosis and management. Clin Infect Dis. 1998;27(1):142-149.
3. Kain KC, MacPherson DW, Kelton T, Keystone JS, Mendelson J, MacLean JD. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. CMAJ. 2001;164(5):654-9.
4. Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil: Report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg. 2007;76(2):208-23.
5. Rose GW, Suh KN, Kain KC, Le Saux N, McCarthy AE. Atovaquone-proguanil resistance in imported falciparum malaria in a young child. Pediatr Infect Dis J. 2008;27(6):567-569.
6. Krudsood S, Patel SN, Tangpukdee N, Thanachartwet W, Leowattana W, Pornpininworakij K, et al. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 2007;76(4):655-8.
7. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis. 2003;37(3):450-451.
8. Kuhn S, Gill MJ, Kain KC. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg. 2005;72(4):407-9.
9. Labbé A, Patel S, Crandall I, Kain KC. A molecular surveillance system for global patterns of drug resistance in imported malaria. Emerg Infect Dis. 2003;9(1):33-6.
10. Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem. 1997;272(7):3961-3966.
11. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 2000;44(8):2100-2108.
12. Cave W, Pandey P, Osrin D, Shlim DR. Chemoprophylaxis use and the risk of malaria in travelers to Nepal. J Travel Med. 2003;10(2):100-5.
13. Lewis MD, Serichantalergs O, Pitarangsi C, Chuanak N, Mason CJ, Regmi LR, et al. Typhoid fever: a massive, single-point source, multidrug-resistant outbreak in Nepal. Clin Infect Dis. 2005;40(4):554-61.
14. Health Canada. Canadian recommendations for the prevention and treatment of malaria among international travellers. Canadian Communicable Disease Report. 2004;30S1
15. Centers for Disease Control and Prevention. Malaria. Arguin PM, Kozarsky PE, Reed C (editors). Health Information for International Travel 2008. Atlanta: US Department of Health and Human Services, Public Health Service: 2007.
16. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 1996;54(1):62-6.
17. Gubler DJ. Dengue and Dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11(3):480-96.
18. Dondorp A, Nosten F, Stepniewska K, Day N, White N. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366(9487):717-725.
19. Severe malaria: A practical handbook. Geneva: World Health Organization: 2008.
20. Mackintosh CL, Beeson JG, Marsh K. Clinical features and pathogenesis of severe malaria. Trends in Parasitology. 2004;20(12):597-603.
21. Idro R, Ndiritu M, Ogutu B, Mithwani S, Maitland K, Berkley J, et al. Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA. 2007;297(20):2232-2240.
22. Meremikwu M, Smith HJ. Blood transfusion for treating malarial anaemia. Cochrane Database of Systematic Reviews. 1999;(Issue 4).